Neurohormonal Activation After Atrial Fibrillation Initiation in Patients Eligible for Catheter Ablation: A Randomized Controlled Study

Overview

Journal J Am Heart Assoc

Specialty Cardiology & Vascular Diseases

Date 2016 Dec 14

PMID 27956398

Citations 5

Authors

Emmanouil Charitakis

Hakan Walfridsson

Eva Nylander

Urban Alehagen

Affiliations

Soon will be listed here.

Abstract

Background: Biomarker activation in atrial fibrillation (AF) has been widely studied, but the immediate effect of AF initiation remains unclear. We studied the effect of AF initiation on 2 cardiac biomarkers: the N-terminal fragment of the proB-type natriuretic peptide (NT-proBNP), the midregional fragment of the N-terminal of pro-atrial natriuretic peptide (MR-proANP), and 2 extracardiac biomarkers-the copeptin and the midregional portion of proadrenomedullin (MR-proADM).

Methods And Results: This was a randomized controlled study, including 45 patients with AF who had been referred for radiofrequency ablation to the University Hospital, Linköping, Sweden, between February 2012 and April 2014. Freedom from AF during the 4 days prior to radiofrequency ablation was confirmed by transtelephonic ECGs. Biomarkers were collected from the femoral vein (fv), coronary sinus (CS), and left atrium (LA) prior to AF initiation (baseline) and 30 minutes later. The MR-proANP and NT-proBNP concentrations increased in the intervention group compared with the control group 30 minutes after the initiation of AF (MR-proANP: P<0.001, P<0.001, P<0.001; NT-proBNP: P<0.001). Copeptin levels in patients without ischemic heart disease were decreased after the initiation of AF (P=0.003, P=0.015, P=0.011).

Conclusions: AF is a strong stimulus that results in immediate activation of different biomarkers.

Clinical Trial Registration: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01553045.

Citing Articles

Spectrum of Non-Obstructive Coronary Artery Disease and Its Relationship with Atrial Fibrillation.

Oancea A, Morariu P, Buburuz A, Miftode I, Miftode R, Mitu O J Clin Med. 2024; 13(16).

PMID: 39201063 PMC: 11355151. DOI: 10.3390/jcm13164921.

Interatrial Block, Bayés Syndrome, Left Atrial Enlargement, and Atrial Failure.

Bejarano-Arosemena R, Martinez-Selles M J Clin Med. 2023; 12(23).

PMID: 38068382 PMC: 10707143. DOI: 10.3390/jcm12237331.

Haemodynamic changes after atrial fibrillation initiation in patients eligible for catheter ablation: a randomized controlled study.

Almroth H, Karlsson L, Carlhall C, Charitakis E Eur Heart J Open. 2023; 3(6):oead112.

PMID: 38025650 PMC: 10655843. DOI: 10.1093/ehjopen/oead112.

Endocrine and Mechanical Cardiacfunction Four Months after Radiofrequency Ablation of Atrialfibrillation.

Charitakis E, OKarlsson L, Carlhall C, Liuba I, Jonsson A, Walfridsson H J Atr Fibrillation. 2021; 14(1):20200454.

PMID: 34950357 PMC: 8691320. DOI: 10.4022/jafib.20200454.

Causal effects of atrial fibrillation on brain white and gray matter volume: a Mendelian randomization study.

Park S, Lee S, Kim Y, Cho S, Kim K, Kim Y BMC Med. 2021; 19(1):274.

PMID: 34814924 PMC: 8611907. DOI: 10.1186/s12916-021-02152-9.

References

Morgenthaler N, Struck J, Alonso C, Bergmann A . Measurement of midregional proadrenomedullin in plasma with an immunoluminometric assay. Clin Chem. 2005; 51(10):1823-9. DOI: 10.1373/clinchem.2005.051110. View

CHUN T, Itoh H, Ogawa Y, Tamura N, Takaya K, Igaki T . Shear stress augments expression of C-type natriuretic peptide and adrenomedullin. Hypertension. 1997; 29(6):1296-302. DOI: 10.1161/01.hyp.29.6.1296. View

Yasue H, Yoshimura M, Sumida H, Kikuta K, Kugiyama K, Jougasaki M . Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation. 1994; 90(1):195-203. DOI: 10.1161/01.cir.90.1.195. View

Jougasaki M, Burnett Jr J . Adrenomedullin: potential in physiology and pathophysiology. Life Sci. 2000; 66(10):855-72. DOI: 10.1016/s0024-3205(99)00358-6. View

Sobocinski P, Anggardh Rooth E, Kull V, von Arbin M, Wallen H, Rosenqvist M . Improved screening for silent atrial fibrillation after ischaemic stroke. Europace. 2012; 14(8):1112-6. DOI: 10.1093/europace/eur431. View

Morgenthaler N . Copeptin: a biomarker of cardiovascular and renal function. Congest Heart Fail. 2010; 16 Suppl 1:S37-44. DOI: 10.1111/j.1751-7133.2010.00177.x. View

Goetze J, Friis-Hansen L, Rehfeld J, Nilsson B, Svendsen J . Atrial secretion of B-type natriuretic peptide. Eur Heart J. 2006; 27(14):1648-50. DOI: 10.1093/eurheartj/ehl109. View

Ellinor P, Low A, Patton K, Shea M, MacRae C . Discordant atrial natriuretic peptide and brain natriuretic peptide levels in lone atrial fibrillation. J Am Coll Cardiol. 2005; 45(1):82-6. DOI: 10.1016/j.jacc.2004.09.045. View

Edwards B, Zimmerman R, Schwab T, Heublein D, Burnett Jr J . Atrial stretch, not pressure, is the principal determinant controlling the acute release of atrial natriuretic factor. Circ Res. 1988; 62(2):191-5. DOI: 10.1161/01.res.62.2.191. View

10.

Morgenthaler N, Struck J, Alonso C, Bergmann A . Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem. 2005; 52(1):112-9. DOI: 10.1373/clinchem.2005.060038. View

11.

Lindberg B, Hambraeus G, Wollmer P, Andersson K . Release of atrial natriuretic peptide during pulmonary artery clamping in man. Clin Physiol. 1997; 17(5):449-58. DOI: 10.1046/j.1365-2281.1997.04949.x. View

12.

Inoue S, Murakami Y, Sano K, Katoh H, Shimada T . Atrium as a source of brain natriuretic polypeptide in patients with atrial fibrillation. J Card Fail. 2000; 6(2):92-6. DOI: 10.1016/s1071-9164(00)90010-1. View

13.

Patton K, Ellinor P, Heckbert S, Christenson R, deFilippi C, Gottdiener J . N-terminal pro-B-type natriuretic peptide is a major predictor of the development of atrial fibrillation: the Cardiovascular Health Study. Circulation. 2009; 120(18):1768-74. PMC: 4132053. DOI: 10.1161/CIRCULATIONAHA.109.873265. View

14.

Mollmann H, Weber M, Elsasser A, Nef H, Dill T, Rixe J . NT-ProBNP predicts rhythm stability after cardioversion of lone atrial fibrillation. Circ J. 2008; 72(6):921-5. DOI: 10.1253/circj.72.921. View

15.

Morgenthaler N, Struck J, Thomas B, Bergmann A . Immunoluminometric assay for the midregion of pro-atrial natriuretic peptide in human plasma. Clin Chem. 2004; 50(1):234-6. DOI: 10.1373/clinchem.2003.021204. View

16.

Friberg L, Bergfeldt L . Atrial fibrillation prevalence revisited. J Intern Med. 2013; 274(5):461-8. DOI: 10.1111/joim.12114. View

17.

Meune C, Vermillet A, Wahbi K, Guerin S, Aelion H, Weber S . Mid-regional pro atrial natriuretic peptide allows the accurate identification of patients with atrial fibrillation of short time of onset: a pilot study. Clin Biochem. 2011; 44(16):1315-9. DOI: 10.1016/j.clinbiochem.2011.08.906. View

18.

Brookes C, Kemp M, Hooper J, Oldershaw P, Moat N . Plasma brain natriuretic peptide concentrations in patients with chronic mitral regurgitation. J Heart Valve Dis. 1998; 6(6):608-12. View

19.

Chatterjee K . Neurohormonal activation in congestive heart failure and the role of vasopressin. Am J Cardiol. 2005; 95(9A):8B-13B. DOI: 10.1016/j.amjcard.2005.03.003. View

20.

Alboni P, Scarfo S, Fuca G, Paparella N, Yannacopulu P . Hemodynamics of idiopathic paroxysmal atrial fibrillation. Pacing Clin Electrophysiol. 1995; 18(5 Pt 1):980-5. DOI: 10.1111/j.1540-8159.1995.tb04738.x. View